CoChat

Economic and Clinical Impact of Multiple Myeloma to Managed Care

Open access
Cook, Richard · 2008 · Journal of Managed Care Pharmacy

The DOI matches its Crossref record.

Abstract

BACKGROUND: Because of the development of novel agents such as immunomodulators, proteasome inhibitors, and bisphosphonates, the standards of care for the multiple myeloma (MM) patient have changed. The costs associated with current and emerging therapies, as well as supportive care, are significant and pose a tremendous financial burden to both patients and managed care. OBJECTIVE: To review the economic impact of MM and to weigh the advantages and disadvantages of current treatments in bringing value for prolonged life versus the cost of treatment. This chapter will also discuss the need for thorough data review and pharmacoeconomic analyses to determine the most cost-effective therapies. SUMMARY: Although MM accounts for only a small percentage of all cancer types, the costs associated with treating and managing it are among the highest. Recent developments in diagnosing, treating, and managing myeloma have led to novel treatment strategies. Immunomodulators, proteasome inhibitors, and bisphosphonates are improving response rates and preserving quality of life. However, these agents are not replacing older treatment modalities, but being used in addition to them. Intensive chemotherapy, stem cell transplantation, and supportive care are all important components in achieving treatment goals. Costs associated with stem cell transplants and complications of the disease add to the economic burden of myeloma. Additional costs for routine diagnostics to measure the progression of the disease or response to treatment need to be considered. Complications (e.g., lytic bone disease, infection, anemia, and renal failure) also add to morbidity and mortality, thus increasing the burden to the patient and the health care system as a whole. Financial and time constraints of caregivers must also be considered, as well as the added administrative burdens to health care providers. CONCLUSION: New standards of care in the treatment and management of myeloma are likely to lead to significant increases in costs. Although costs are not the only elements to be considered, they are crucial in the management of this already costly disease. All aspects of myeloma treatment and supportive care must be evaluated and analyzed. Cost of pharmaceuticals alone must not be a driving factor in treatment decisions. Economic analyses can be used to demonstrate that the least expensive alternative is not always the most economical, and that it may not produce an optimal outcome for both the health plan and the patient. Although cost containment is clearly an important objective, quality of care is the first priority, and managed care organizations have the challenge of making balanced cost and benefit assessments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18553/jmcp.2008.14.s7-a.19

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Still being checked.

Research works printed but not linked: 16

  1. [3]3. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109:2334-42.
  2. [5]5. Cancer Facts and Figures 2008. CA Cancer J Clin. 2008;58:71-96. Available at: www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_ and_Figures_2008.asp?from=fast. Accessed March 24, 2008.
  3. [8]8. Cook R. An economic perspective on treatment options in multiple myeloma. Managed Care Oncol. Spring 2007;3:10-12.
  4. [11]11. Jones JA, Qazilbash MH, Shih YT, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignan- cies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008;112:1096-105.
  5. [12]12. Meehan KR, Fitzmaurice T, Root L, Kimtis E, Patchett L, Hill J. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients. J Support Oncol. 2006;4:187-90.
  6. [13]13. Djulbegovic B, Kumar A. Multiple myeloma: detecting the effects of new treatments. Lancet. 2008;371:1642-44.
  7. [14]14. Schwartzberg L. Managed care considerations in the treatment of multiple myeloma. Managed Care Oncol. Spring 2007;3:14-16, 47.
  8. [16]16. Barosi G, Boccadoro M, Cavo M, et al. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:717-41.
  9. [17]17. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol. 2005;28:8-16.
  10. [18]18. McKeage K, Plosker GL. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics. 2008;26:251-68.
  11. [19]19. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol.1998;16:1218-25.
  12. [20]20. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphos- phonates in multiple myeloma. J Clin Oncol. 2007;25:2464-72.
  13. [21]21. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-3.
  14. [22]22. Coyte PC, Dobrow MJ, Broadfield L. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics. 2001;19:845-54.
  15. [23]23. Saad F, Lipton A, Cook R, et al. Pathological fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-67.
  16. [24]24. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboem- bolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-505.

Cited by

See all 52

Metadata

Authors
Cook, R.
Corresponding author
Cook, Richard
Venue
Journal of Managed Care Pharmacy
Published
2008-09
Volume
14
Issue
7 Supp A
Pages
19-25
ISSN
  • 1083-4087 (ISSN-L)
  • 1944-706X
OpenAlex
W132940748
Cited by
52
References
0
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
1.52
Type
journal article
Language
en
Open access
Locations
  • Journal of Managed Care Pharmacy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
multiple myeloma, economic burden, health care costs, managed care, pharmacoeconomics, cost-effectiveness, immunomodulators, proteasome inhibitors, bisphosphonates, stem cell transplantation, supportive care, cost containment, quality of care, caregiver burden
MeSH terms
Antineoplastic Agents, Humans, Managed Care Programs, Multiple Myeloma, United States, Drug Costs, Health Care Costs, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic and Clinical Impact of Multiple Myeloma to Managed Care. https://app.cochat.ai/papers/10.18553/jmcp.2008.14.s7-a.19
The paper
Cook, R. (2008). Economic and Clinical Impact of Multiple Myeloma to Managed Care. Journal of Managed Care Pharmacy. https://doi.org/10.18553/jmcp.2008.14.s7-a.19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.